Lishengpharma(SZ:002393) Zheng Quan Ri Bao Zhi Sheng·2025-12-17 12:44Core Viewpoint - The company focuses on the pharmaceutical health industry, implementing a strategic approach of "focusing on core, three forces combined, comprehensive innovation, and win-win cooperation" through the "23456" strategy [1] Group 1: Strategic Focus - The company aims to drive development through a "dual-wheel" approach, enhancing its capabilities by building "three major advantages," establishing "four major sectors," and targeting "five major fields" [1] - The core objective is to achieve a virtuous cycle of "research driving sales, and sales supporting research," ultimately enhancing the company's core competitiveness, industry influence, and international capabilities [1] Group 2: Business Specialization - The company's business focus is reflected in the specialized positioning of its subsidiaries: - The main company serves as the production base for oral solid preparations - Central Pharmaceutical is the production base for soft capsules - Biochemical Pharmaceuticals focuses on sterile preparations - Kunlun Pharmaceuticals is dedicated to active pharmaceutical ingredients - Youth Health Source specializes in traditional Chinese medicine production [1] Group 3: Innovation and Investment - The company emphasizes "comprehensive innovation," leveraging the opportunity of the science and technology reform demonstration to enhance corporate vitality through mechanism, product, technology, marketing, and business model innovations [1] - The company participates in establishing an industrial pharmaceutical fund, focusing on investments in innovative drugs, medical devices, and biotechnology within the health sector, reflecting its "win-win cooperation" strategy [1] - The goal of the fund is to integrate industry resources and provide project reserves and synergistic effects for the long-term development of its main business, rather than shifting focus to cash management [1]